BTK and atrial fibrillation: Although ibrutinib, the first-generation BTK inhibitor, has been pioneering in the treatment of B-cell lymphoma, its adverse reactions are also worthy of attention, such as atrial fibrillation bleeding, diarrhea, rash, atrial fibrillation, and neutropenia (Davids and Brown, 2014; Paydas, 2019).